Navigation Links
Medivation Announces Third Quarter 2010 Financial Results Teleconference and Webcast on November 5, 2010
Date:10/29/2010

SAN FRANCISCO, Oct. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2010 financial results and provide a general business update on November 5, 2010, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2010 will be released after markets close on November 5, 2010.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
2. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
3. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
4. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
5. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
6. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
7. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
8. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/29/2016)... -- Automation is one of the best ... growing demands for productivity in speed, accuracy, throughput and ... already adept of a wide range of functions that ... Instrumentation continues to evolve, and is poised to tackle ... years ago. Originally used mostly by the big pharmaceutical ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
Breaking Medicine News(10 mins):